Cocrystal Pharma raises $1.03M in private placement with four insider investors at $1.39/unit

Cocrystal Pharma, Inc.

Sold 739,426 units (1 share + 2 warrants) at $1.39/unit for $1.03M to four accredited insider purchasers.
Warrants exercisable at $1.24/share for 27 months; potential additional $1.83M if fully exercised.
Insiders include Directors Phillip Frost, Fred Hassan, Richard Pfenniger, and co-CEO/CFO James Martin.
Proceeds to support clinical antiviral development programs and general working capital.
Offering exempt under Section 4(a)(2) and Regulation D; no registration rights granted.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Cocrystal Pharma, Inc. issued 739,426 units of unit to four accredited investors (the “Purchasers”) for $1.39 per unit; gross proceeds were $1.03 million.

Security: unit
Shares: 739,426 units
Purchaser: four accredited investors (the “Purchasers”)
Consideration: $1.39 per unit; gross proceeds were $1.03 million

Exact text from the filing

On October 28, 2025, Cocrystal Pharma, Inc., a Delaware corporation (the “Company” or “Cocrystal”) entered into a Securities Purchase Agreement (“SPA”) with four accredited investors (the “Purchasers”) under which the Purchasers purchased a total of 739,426 units of the Company’s securities. The units were priced at-the-market under the rules of the Nasdaq Stock Market at a purchase price of $1.39 per unit. Each unit consisted of one share of common stock and one warrant to purchase two shares of common stock at an exercise price of $1.24 per share over a 27-month period.

View on SEC.gov

Browse all equity issuances →

Cocrystal Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-020143

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.